Brought to you by 
Novartis invests in Selexys with exclusive option to acquire the company; option exercised
02 Aug 2022
Executive Summary
Novartis Pharmaceuticals Corp. has been granted an exclusive option to acquire closely held Selexys Pharmaceuticals Corp. (therapeutics for inflammatory and thrombotic diseases) after it completes a Phase II study of the anti-P-selectin antibody SelG1, which recently finished Phase I for vaso-occlusive crisis, a major complication in patients with sickle cell disease.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes M&A Option
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis invests in Selexys with exclusive option to acquire the company; option exercised
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice